Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine -- Ten shingles cases would have been expected absent ...

"These data support our efforts to bring a new shingles vaccine to global markets,” stated George Simeon, Curevo's Chief Executive Officer. "Though somewhat unsurprising, given amezosvatein also ...

High-dose amezosvatein and Shingrix generated similar serum neutralizing antibodies to the varicella zoster virus (VZV) and T-cell responses specific for the gE antigen. Vaccines are studied for ...

Adults should discuss with their doctors about whether this vaccine is necessary. It is recommended that adults 50 and older ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...